Idera Pharmaceuticals to Effect a Reverse Stock Split
June 22 2006 - 9:00AM
Business Wire
Idera Pharmaceuticals (AMEX: IDP) today announced that its Board of
Directors has authorized a one-for-eight reverse split of the
Company's common stock. The reverse stock split was approved by the
Company's stockholders at the annual meeting of stockholders held
on June 7, 2006. The Company plans the reverse stock split to take
effect after the close of trading on June 29, 2006. "The reverse
stock split marks the achievement of another milestone in Idera's
corporate transformation. These accomplishments include the
establishment of a major corporate partnership, rebranding of the
Company to reflect our focus on Toll-like Receptor-targeted
therapeutics, and securing new funds to advance our programs,"
commented Sudhir Agrawal, D. Phil., Chief Executive Officer of
Idera. "We believe that the recent expansion of our preclinical
development programs to include drug candidates targeting TLRs 7
and 8, in addition to our clinical programs targeting TLR9,
positions us with a broad portfolio of TLR-targeted therapeutics
that is unique in the industry. The candidates generated by these
programs should provide Idera with additional opportunities for our
proprietary development pipeline and create new opportunities to
develop collaborative alliances as Idera moves forward." Upon
effect of the reverse split, each eight shares of Idera's issued
and outstanding common stock will automatically be combined into
and become one share of common stock. No fractional shares will be
issued in connection with the reverse stock split, and holders of
fractional shares will receive cash in lieu of their fractional
shares. After giving effect to the reverse stock split, the Company
will have approximately 16.7 million shares outstanding. Idera
anticipates that its common stock will begin trading on a
split-adjusted basis when trading opens on Friday, June 30, 2006.
Idera's transfer agent, Mellon Investor Services, will mail
instructions to stockholders of record as of the close of business
on June 29, 2006 regarding the exchange of certificates for common
stock. About Idera Pharmaceuticals, Inc. Idera Pharmaceuticals is a
drug discovery and development company with a pipeline of drug
candidates to treat cancer, infectious, respiratory, and autoimmune
diseases. Idera's proprietary drug candidates are designed to
modulate Toll-like Receptors (TLRs,) the body's first line of
immune defense. Idera's pioneering DNA chemistry expertise enables
it to identify drug candidates for internal development and creates
opportunities to develop multiple collaborative alliances. Idera's
most advanced clinical candidate, IMO-2055, is an agonist of TLR9
and is currently in a Phase 2 trial in oncology, and in a Phase 1/2
chemotherapy combination trial in oncology. Idera has selected a
second TLR9 agonist, IMO-2125, as a lead candidate for treating
infectious diseases. Idera also is collaborating with Novartis for
the discovery, optimization, development, and commercialization of
additional TLR9 agonist candidates for asthma and allergy. For more
information, visit www.iderapharma.com. Forward Looking Statements
This press release contains forward-looking statements concerning
Idera Pharmaceuticals, Inc. that involve a number of risks and
uncertainties. For this purpose, any statements contained herein
that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing, the
words "believes," "anticipates," "plans," "expects," "estimates,"
"intends," "should," "could," "will," "may," and similar
expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause Idera's
actual results to differ materially from those indicated by such
forward-looking statements, including whether products based on
Idera's technology such as IMO-2055 will advance into or through
the clinical trial process on a timely basis or at all and receive
approval from the United States Food and Drug Administration or
equivalent foreign regulatory agencies; whether the Company will
complete enrollment of clinical trials in the time expected;
whether, if the Company's products such as IMO-2055 receive
approval, they will be successfully distributed and marketed;
whether the results of preclinical studies will be indicative of
results that may be obtained in clinical trials; whether Idera's
cash resources will be sufficient to fund product development and
clinical trials; the potential impact of the announced reverse
stock split on our stock price and such other important factors as
are set forth under the caption "Risk Factors" in Idera's Quarterly
Report on Form 10-Q filed on May 12, 2006, which important factors
are incorporated herein by reference. Idera disclaims any intention
or obligation to update any forward-looking statements.
Idera Pharmaceutical (AMEX:IDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Idera Pharmaceutical (AMEX:IDP)
Historical Stock Chart
From Jul 2023 to Jul 2024